Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice
- PMID: 19177596
- DOI: 10.1002/hep.22774
Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice
Abstract
Hepatic steatosis is a hallmark of nonalcoholic fatty liver disease (NAFLD) and a key component of obesity-associated metabolic dysfunctions featuring dyslipidemia, insulin resistance, and loss of glycemic control. It has yet to be completely understood how much dysregulated de novo lipogenesis contributes to the pathogenic development of hepatic steatosis and insulin resistance. ATP-citrate lyase (ACL) is a lipogenic enzyme that catalyzes the critical reaction linking cellular glucose catabolism and lipogenesis, converting cytosolic citrate to acetyl-coenzyme A (CoA). Acetyl-CoA is further converted to malonyl-CoA, the essential precursor for fatty acid biosynthesis. We investigated whether dysregulation of hepatic ACL is metabolically connected to hepatic steatosis, insulin resistance, and hyperglycemia. We found that in leptin receptor-deficient db/db mice, the expression of ACL was selectively elevated in the liver but not in the white adipose tissue. Liver-specific ACL abrogation via adenovirus-mediated RNA interference prominently reduced the hepatic contents of both acetyl-CoA and malonyl-CoA, markedly inhibited hepatic de novo lipogenesis, and protected against hepatic steatosis in db/db mice. Surprisingly, liver-specific ACL abrogation markedly inhibited the expression of peroxisome proliferator-activated receptor-gamma and the entire lipogenic program in the liver. Moreover, hepatic ACL deficiency resulted in significantly down-regulated expression of gluconeogenic genes in the liver as well as enhanced insulin sensitivity in the muscle, leading to substantially improved systemic glucose metabolism.
Conclusion: These findings establish a crucial role of hepatic ACL in lipid and glucose metabolism; therefore, hepatic ACL may serve as a potential target to treat NAFLD and type 2 diabetes.
Similar articles
-
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.J Endocrinol. 2017 Jul;234(1):R1-R21. doi: 10.1530/JOE-16-0513. Epub 2017 Apr 20. J Endocrinol. 2017. PMID: 28428362 Review.
-
Involvement of regucalcin in lipid metabolism and diabetes.Metabolism. 2013 Aug;62(8):1045-51. doi: 10.1016/j.metabol.2013.01.023. Epub 2013 Feb 28. Metabolism. 2013. PMID: 23453039 Review.
-
Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.Int J Obes (Lond). 2011 Aug;35(8):1019-30. doi: 10.1038/ijo.2010.256. Epub 2010 Dec 14. Int J Obes (Lond). 2011. PMID: 21157426
-
Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice.J Lipid Res. 2010 Sep;51(9):2516-26. doi: 10.1194/jlr.M003335. Epub 2010 May 20. J Lipid Res. 2010. PMID: 20488800 Free PMC article.
-
Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.Diabetes. 2006 Aug;55(8):2159-70. doi: 10.2337/db06-0200. Diabetes. 2006. PMID: 16873678
Cited by
-
The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with type 2 diabetes mellitus: recent findings from NHANES 2007-2018.Lipids Health Dis. 2024 May 21;23(1):151. doi: 10.1186/s12944-024-02143-8. Lipids Health Dis. 2024. PMID: 38773578 Free PMC article.
-
Nanozyme as a rising star for metabolic disease management.J Nanobiotechnology. 2024 May 6;22(1):226. doi: 10.1186/s12951-024-02478-5. J Nanobiotechnology. 2024. PMID: 38711066 Free PMC article. Review.
-
Blautia Coccoides is a Newly Identified Bacterium Increased by Leucine Deprivation and has a Novel Function in Improving Metabolic Disorders.Adv Sci (Weinh). 2024 May;11(18):e2309255. doi: 10.1002/advs.202309255. Epub 2024 Mar 1. Adv Sci (Weinh). 2024. PMID: 38429906 Free PMC article.
-
Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models.JCI Insight. 2023 Sep 8;8(17):e161282. doi: 10.1172/jci.insight.161282. JCI Insight. 2023. PMID: 37681411 Free PMC article.
-
Insulin Regulation of Hepatic Lipid Homeostasis.Compr Physiol. 2023 Jun 26;13(3):4785-4809. doi: 10.1002/cphy.c220015. Compr Physiol. 2023. PMID: 37358513 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous